CPA Applauds Court of International Trade Ruling Upholding the End of the De Minimis Loophole

CPA Applauds Court of International Trade Ruling Upholding the End of the De Minimis Loophole

For years, the de minimis loophole allowed foreign shippers to send packages valued at up to $800 into the United States duty-free, tax-free, and with virtually no customs scrutiny — so long as the foreign vendor merely alleged the value was below the threshold.

CPA Applauds President Trump’s Section 232 Proclamation Securing America’s Polysilicon and Solar Supply Chain

CPA Applauds President Trump’s Section 232 Proclamation Securing America’s Polysilicon and Solar Supply Chain

Today’s Section 232 proclamation secures that foundation, and the entire structure is built to reward one thing: manufacturing in America. Companies investing in U.S. polysilicon, wafer, and cell production are the clear winners, and companies that continue to rely on imports will be at a disadvantage.

CPA Releases New Report Urging Treasury and USTR to Reject USMCA Aluminum Exemptions, Strengthen Downstream Tariffs

CPA Releases New Report Urging Treasury and USTR to Reject USMCA Aluminum Exemptions, Strengthen Downstream Tariffs

Findings show that U.S. tariff policy leaves the aluminum industry’s largest employment base exposed, even as primary aluminum tariff costs are passed on to extruders and fabricators.

New CPA Report: America Now Makes Just 27% of the Medicine It Consumes, Down From 72% in 2002

New CPA Report: America Now Makes Just 27% of the Medicine It Consumes, Down From 72% in 2002

This report shows in stark numbers what American patients and pharmacists already feel every day – our medicine cabinet has been hollowed out, and we are now dangerously dependent on a handful of foreign, sometimes even adversarial, countries for the drugs that keep people alive.

CPA Welcomes FDA Proposal to Expose Hidden Foreign Suppliers in America’s Drug Supply Chain

CPA Welcomes FDA Proposal to Expose Hidden Foreign Suppliers in America’s Drug Supply Chain

For years, the most critical link in our drug supply chain — the upstream chemistry — has been invisible to our own regulators. A medicine finished in Europe is not necessarily a European medicine, and this rule finally begins to expose that fiction.